The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications.

CONCLUSION: Decline in eGFR over 2 years is associated with increased risk of clinical outcomes beyond the effects of baseline eGFR. These risks were the same irrespective of the primary medication used to treat HTN. PMID: 29360915 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29360915?dopt=Abstract

Source: American Journal of Hypertension - January 19, 2018 Category: Cardiology Authors: Barzilay JI, Davis BR, Pressel SL, Ghosh A, Rahman M, Einhorn PT, Cushman WC, Whelton PK, Wright JT Tags: Am J Hypertens Source Type: research